Saturday, June 1, 2024

6:30 PM – 7:30 PM CT

Please note this live virtual meeting is at: 7:30 PM Eastern; 6:30 PM Central; 5:30 PM Mountain; 4:30 PM Pacific

This enduring educational activity will focus primarily on risk stratification and best practices to more accurately inform treatment sequencing in patients with relapsed/refractory multiple myeloma; explore mechanisms of action of innovative therapies for multiple myeloma; and evaluate new and emerging bispecific anti-BCMA and anti-FcRH5 clinical trial data in the setting of relapsed/refractory multiple myeloma.

RELEASED DATE: April 26, 2024
EXPIRATION DATE: April 26, 2025

Monday, March 29, 2021

12:00 PM – 1:00 PM ET

This virtual program is at 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain, and 9:00AM Pacific.

Thursday, May 16, 2024

10:00AM – 11:00AM ET

Please note this activity is at 10:00AM Eastern, 9:00AM Central, 8:00AM Mountain and 7:00AM Pacific.

In this activity we will discuss the relevance of specific genetic and molecular markers in Chronic Lymphocytic Leukemia (CLL), review the current evidence concerning the application of minimal residual disease (MRD) monitoring, and emerging strategies and combinations for CLL management in first-line and relapsed/refractory settings. Finally, we will examine the potential adverse events associated with CLL therapeutics, including specific considerations with combination therapies.

RELEASED DATE: September 08, 2023
EXPIRATION DATE: September 08, 2024

This educational activity is designed to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC. We aim to discuss both the VA oncology clinical pathways and oncology precision program to guide personalized NSCLC care; evaluate immune checkpoint monotherapy clinical findings in the front-line treatment of patients with advanced NSCLC without targetable mutations; and examine the trials data for PD-1 inhibitor/chemotherapy combinations in the front-line management of patients with advanced NSCLC and no targetable mutations.

RELEASED DATE: August 15, 2023
EXPIRATION DATE: August 15, 2024

These enduring activities use a unique documentary approach to share the patient experience of diagnosis and treatment of cutaneous malignancies. It highlights their experiences with surgery, radiation, chemotherapy, and immunotherapy with commentary from our faculty expert. The goal is to help learners identify potential immune targets and systemic treatment strategies; optimize multidisciplinary management; and incorporate shared decision making in arriving at individualized care for their patients with cutaneous malignancies.

RELEASED DATE: January 31, 2024
EXPIRATION DATE: January 31, 2025

These educational Whiteboard Snapshot online enduring programs focus on the latest updates in novel-targeted and immunotherapeutic approaches of cutaneous malignancies, including identifying targetable mutations and determining eligibility for immunotherapy. Additional considerations regarding pearls for adverse event recognition and management, as well as leveraging shared decision making and the multidisciplinary team are included as part of a comprehensive approach to care in cutaneous malignancies.

RELEASED DATE: December 12, 2023
EXPIRATION DATE: December 12, 2024

This program addresses current evidence-based perspectives in first-line management of advanced non-small cell lung cancer (NSCLC) in the first-line setting based on biomarkers, tumor histology, and patient-specific factors. By analyzing current clinical trial data and patient subgroups, clinicians will gain an understanding of therapeutic strategies, including checkpoint inhibitor monotherapy and checkpoint inhibitors in combination with chemotherapy. Given updates in the early-line management of NSCLC, it is crucial for multidisciplinary health care professionals to maintain awareness of novel combinations and potential adverse events associated with therapy, including immune-related adverse events. This program will emphasize best practices in multidisciplinary management, adverse event monitoring, and ongoing care to optimize therapeutic outcomes.

RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024

This online program is designed to help oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician's assistants to ensure confidence in the management of advanced melanoma. We aim to evaluate the pathophysiology of melanoma, including the rationale for use of anti-LAG3 antibodies in combination in advanced melanoma; assess the latest clinical data and clinical trial opportunities concerning the use of anti-LAG3 antibodies for combination in advanced melanoma; and recognize safety data with combination immunotherapy approaches in advanced melanoma.

RELEASED DATE: March 03, 2023
EXPIRATION DATE: March 03, 2024